Parkinson's Needs FDA Flexibility, NIH Funding Certainty
This article was originally published in Scrip
With Parkinson's affecting about six million people worldwide – with some estimates putting it as high as 10 million – and the condition becoming increasingly burdensome on health systems around the globe, "we don't have to do a lot of convincing" the disease is worthwhile to invest in and pursue for new treatments, said Todd Sherer, CEO of the Michael J. Fox Foundation (MJFF).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.